995 related articles for article (PubMed ID: 18363998)
1. Multiple roles for CD4+ T cells in anti-tumor immune responses.
Kennedy R; Celis E
Immunol Rev; 2008 Apr; 222():129-44. PubMed ID: 18363998
[TBL] [Abstract][Full Text] [Related]
2. Tumor-infiltrating dendritic cell subsets of progressive or regressive tumors induce suppressive or protective immune responses.
Liu Y; Bi X; Xu S; Xiang J
Cancer Res; 2005 Jun; 65(11):4955-62. PubMed ID: 15930318
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
[TBL] [Abstract][Full Text] [Related]
4. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
[TBL] [Abstract][Full Text] [Related]
5. Immune response of human propagated gammadelta-T-cells to neuroblastoma recommend the Vdelta1+ subset for gammadelta-T-cell-based immunotherapy.
Schilbach K; Frommer K; Meier S; Handgretinger R; Eyrich M
J Immunother; 2008; 31(9):896-905. PubMed ID: 18832998
[TBL] [Abstract][Full Text] [Related]
6. Molecular immunological approaches to biotherapy of human cancers--a review, hypothesis and implications.
Becker Y
Anticancer Res; 2006; 26(2A):1113-34. PubMed ID: 16619514
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs.
Osada T; Morse MA; Lyerly HK; Clay TM
Int Immunol; 2005 Sep; 17(9):1143-55. PubMed ID: 16027139
[TBL] [Abstract][Full Text] [Related]
8. Sustained antigen-specific antitumor recall response mediated by gene-modified CD4+ T helper-1 and CD8+ T cells.
Moeller M; Kershaw MH; Cameron R; Westwood JA; Trapani JA; Smyth MJ; Darcy PK
Cancer Res; 2007 Dec; 67(23):11428-37. PubMed ID: 18056471
[TBL] [Abstract][Full Text] [Related]
9. Expression of Foxp3+CD4+CD25+ regulatory T cells and Th1/Th2, Tc1/Tc2 profiles in the peripheral blood of patients with condyloma acuminatum.
Xu Y; Zhu KJ; Zhu N; Jiang DH; Chen XZ; Cheng H
Clin Exp Dermatol; 2009 Mar; 34(2):229-35. PubMed ID: 19077104
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-18 regulates T helper 1 or 2 immune responses of human cord blood CD4+ V alpha 24+V beta 11+ natural killer T cells.
Fujibayashi Y; Fujimori Y; Kasumoto I; Kai S; Hara H; Okamura H; Tsutsui H; Ogawa H; Nakanishi K
Int J Mol Med; 2007 Aug; 20(2):241-5. PubMed ID: 17611643
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
12. [New insights into cytotoxic effector cells].
Rey J; Olive D; Sébahoun G; O'Callaghan T; Costello RT
Bull Cancer; 2005 Nov; 92(11):935-43. PubMed ID: 16316827
[TBL] [Abstract][Full Text] [Related]
13. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression.
Ghiringhelli F; Ménard C; Martin F; Zitvogel L
Immunol Rev; 2006 Dec; 214():229-38. PubMed ID: 17100888
[TBL] [Abstract][Full Text] [Related]
14. Lineage and signal strength determine the inhibitory effect of transforming growth factor beta1 (TGF-beta1) on human antigen-specific Th1 and Th2 memory cells.
Holzer U; Rieck M; Buckner JH
J Autoimmun; 2006 Jun; 26(4):241-51. PubMed ID: 16730947
[TBL] [Abstract][Full Text] [Related]
15. The significance of Treg cells in defective tumor immunity.
Kosmaczewska A; Ciszak L; Potoczek S; Frydecka I
Arch Immunol Ther Exp (Warsz); 2008; 56(3):181-91. PubMed ID: 18512029
[TBL] [Abstract][Full Text] [Related]
16. Control of immune responses by immunoregulatory T cells.
Rudge G; Gleeson PA; van Driel IR
Arch Immunol Ther Exp (Warsz); 2006; 54(6):381-91. PubMed ID: 17122882
[TBL] [Abstract][Full Text] [Related]
17. Branched and linear lipopeptide vaccines have different effects on primary CD4+ and CD8+ T-cell activation but induce similar tumor-protective memory CD8+ T-cell responses.
Baz A; Buttigieg K; Zeng W; Rizkalla M; Jackson DC; Groves P; Kelso A
Vaccine; 2008 May; 26(21):2570-9. PubMed ID: 18420312
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic efficacy of antitumor dendritic cell vaccinations correlates with persistent Th1 responses, high intratumor CD8+ T cell recruitment and low relative regulatory T cell infiltration.
Driessens G; Gordower L; Nuttin L; Stordeur P; Blocklet D; Egrise D; Velu T; Bruyns C
Cancer Immunol Immunother; 2008 Dec; 57(12):1745-56. PubMed ID: 18369621
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of Foxp3(+) gammadelta T cells in mouse and human.
Kang N; Tang L; Li X; Wu D; Li W; Chen X; Cui L; Ba D; He W
Immunol Lett; 2009 Aug; 125(2):105-13. PubMed ID: 19539651
[TBL] [Abstract][Full Text] [Related]
20. NKT cells and tumor immunity--a double-edged sword.
Smyth MJ; Godfrey DI
Nat Immunol; 2000 Dec; 1(6):459-60. PubMed ID: 11101862
[No Abstract] [Full Text] [Related]
[Next] [New Search]
